European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes

被引：0
|
作者：
Bowen, D. [1 ]
Droste, J. [2 ]
Smith, A. [3 ]
Fenaux, P. [4 ]
Symeonidis, A. [5 ]
Sanz, G. [6 ]
Hellstrom-Lindberg, E. [7 ]
Cermak, J. [8 ]
Gologan, R. [9 ]
Germing, U. [10 ]
Stauder, R. [11 ]
Malcovati, L. [12 ]
de Witte, T. [2 ]
机构：
[1] Leeds Teaching Hosp, Leeds, W Yorkshire, England
[2] Univ Nijmegen, Nijmegen, Netherlands
[3] Univ York, York YO10 5DD, N Yorkshire, England
[4] Hop Avicenne, F-93009 Bobigny, France
[5] Univ Patras, GR-26110 Patras, Greece
[6] Hosp Univ La Fe, Valencia, Spain
[7] Karolinska Inst, Stockholm, Sweden
[8] Charles Univ Prague, Prague, Czech Republic
[9] Fundeni Clin Inst, Bucharest, Romania
[10] Univ Dusseldorf, Dusseldorf, Germany
[11] Innsbruck Med Univ, Innsbruck, Austria
[12] Univ Pavia, I-27100 Pavia, Italy
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70095-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [1] Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry
    De Swart, Louise
    Reiniers, Chloe
    Bagguley, Tim
    van Marrewijk, Corine
    Bowen, David
    Cermak, Jaroslav
    Hellstrom-Lindberg, Eva
    Tatic, Aurelia
    Symeonidis, Argiris
    Huls, Gerwin A.
    Smith, Alex
    de Witte, Theo
    BLOOD, 2014, 124 (21)
  • [2] Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Sekeres, Mikkael A.
    List, Alan F.
    Khoury, H. Jean
    Advani, Anjali
    Jabbour, Elias
    Kantarjian, Hagop M.
    Lancet, Jeffrey E.
    Cable, LouAnn
    Guthrie, Kari
    Hogeland, Grant
    Ptaszynski, Mieke
    Maloney, Lara
    Corson, Donald
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
  • [3] IMPACT OF MDS ON HEALTH-RELATED QUALITY OF LIFE: A COMPARISON OF IPSS LOW-AND INT-1 RISK MDS PATIENTS FROM THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY AND EUROPEAN REFERENCE POPULATIONS
    Stauder, R.
    Bagguley, T.
    Smith, A.
    Fenaux, P.
    Symeonidis, A.
    Cermak, J.
    Sanz, G.
    Hellstrom-Lindberg, E.
    Mittelman, M.
    Malcovati, L.
    Huls, G.
    Madry, K.
    Germing, U.
    Tatic, A.
    Holm, M. S.
    Savic, A.
    Droste, J.
    Guerci-Bresler, A.
    Slama, B.
    Luno, E.
    Culligan, D.
    de Swart, L.
    Johnston, W. T.
    Bowen, D.
    de Witte, T.
    HAEMATOLOGICA, 2015, 100 : 68 - 69
  • [4] COMPASIVE USE OF 5-AZACITIDINE IN PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES
    Dunia, D. M.
    Nuria, G.
    Miguel, D.
    Jaime, A.
    Helga, G.
    Dolores, S.
    Dolores, M.
    Blanca, P.
    Cristina, F.
    Alejandro, V.
    Sonia, H.
    HAEMATOLOGICA, 2016, 101 : 773 - 774
  • [5] COMPASIVE USE OF 5-AZACITIDINE IN PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES
    de Miguel, D.
    Golbano, N.
    San Roman, I.
    Arbeteta, J.
    Diaz, M.
    Morales, D.
    Herrero, S.
    Subira, D.
    PInedo, B.
    HAEMATOLOGICA, 2012, 97 : 581 - 581
  • [6] EFFECTS OF ERYTHROPOIESIS-STIMULATING AGENTS ON OVERALL SURVIVAL OF IPSS LOW/INT-1 RISK TRANSFUSION INDEPENDENT MYELODYSPLASTIC SYNDROMEPATIENTS, A FISM STUDY
    Messa, E.
    Gioia, D.
    Masiera, E.
    Castiglione, A.
    Ceccarelli, M.
    Salvi, F.
    Danise, P.
    Sanna, A.
    Allione, B.
    Balleari, E.
    Poloni, A.
    Cametti, G.
    Ferrero, D.
    Tassara, R.
    Finelli, C.
    Bonferroni, M.
    Ciccone, G.
    Saglio, G.
    Levis, A.
    Santini, V.
    LEUKEMIA RESEARCH, 2017, 55 : S58 - S58
  • [7] Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study
    Della Porta, Matteo G.
    Picone, Cristina
    Pascutto, Cristiana
    Malcovati, Luca
    Tamura, Hideto
    Handa, Hiroshi
    Czader, Magdalena
    Freeman, Sylvie
    Vyas, Paresh
    Porwit, Anna
    Saft, Leonie
    Westers, Theresia M.
    Alhan, Canan
    Cali, Claudia
    van de Loosdrecht, Arjan A.
    Ogata, Kiyoyuki
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (08): : 1209 - 1217
  • [8] Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes
    Komrokji, Rami S.
    List, Alan F.
    Khoury, H. Jean
    Lancet, Jeffrey E.
    Jabbour, Elias
    Foudray, Maria C.
    Winski, Shannon L.
    Bell, Stacie
    Rush, Selena Armistead
    Maloney, Lara
    Ptaszynski, Ann Marie
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2011, 118 (21) : 58 - 58
  • [9] p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes
    Frisan, Emilie
    Pawlikowska, Patrycja
    Pierre-Eugene, Cecile
    Viallon, Vivian
    Gibault, Laure
    Park, Sophie
    Mayeux, Patrick
    Dreyfus, Francois
    Porteu, Francoise
    Fontenay, Michaela
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1964 - 1968
  • [10] MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY
    Picone, C.
    Tenore, A.
    Vanelli, L.
    Malcovati, L.
    Pascutto, C.
    Ogata, K.
    Tamura, H.
    Handa, H.
    Czader, M.
    Freeman, S.
    Vyas, P.
    Porwit, A.
    Saft, L.
    Westers, T. M.
    Alhan, C.
    Cali, C.
    van de Loosdrecht, A. A.
    Cazzola, M.
    Della Porta, M. G.
    CYTOMETRY PART A, 2011, 79A (12) : 1051 - 1052
12345